Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2CNS 2Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Sunitinib 3Trastuzumab 2Temozolomide 2Magnetic Resonance Spectroscopy 2Capecitabine 2Bortezomib 2tovorafenib 1tipifarnib 1telotristat ethyl 1surufatinib 1sintilimab 1selpercatinib 1sargramostim 1romidepsin 1pasireotide 1milademetan 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1folfirinox 1fludarabine phosphate 1fludarabine 1entrectinib 1entinostat 1copper dotatate CU-64 1alectinib 1aldesleukin 1Topotecan 1Taxes 1TH 302 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × tovorafenib × Endocrine × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡